Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
FTC puts conditions on Abbott's proposed $25 billion acquisition of St. Jude Medical, requiring divestiture of two medical device businesses to settle…
announced that it had entered into an agreement dated September 14, 2016 to sell Abbott Medical Optics ("AMO"), its vision care business, to Johnson Johnson…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
announced that it had entered into an agreement dated September 14, 2016 to sell Abbott Medical Optics ("AMO"), its vision care business, to Johnson Johnson for $4.325 billion in cash, subject to customary purchase price adjustments for cash, debt, and working capital.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Abbott Laboratories / St. Jude Medical (this deal) | 2016 | $25.0B | 75 |
| Abbott Laboratories / Knoll Pharmaceutical Company (BASF Pharma) | 2001 | $6.9B | 100 |
| Abbott Laboratories / Knoll Pharmaceuticals (BASF Pharma) | 2000 | $6.9B | 95 |
| Abbott Laboratories / Alere Inc. | 2016 | $5.8B | 95 |
| Abbott Laboratories / St. Jude Medical | 2016 | $30.5B | 82 |
| Abbott Laboratories / TheraSense Inc. | 2004 | $1.2B | 81 |
| Abbott Laboratories / Vysis Inc. | 2001 | $355M | 79 |
← Browse all deals · How we score deals
More: 2016 deals · Abbott Laboratories deals · Multiple (undisclosed) deals